Royal Philips and HeartFlow Inc. have entered into a collaboration agreement with the goal of improving access to diagnostic and planning tools for interventional cardiologists evaluating and treating patients with suspected coronary artery disease (CAD). Under the agreement, Philips will promote the use of the HeartFlow FFRct analysis in conjunction with Philips' advanced catheters for imaging and assessing measurements of the inside of a patient's coronary arteries.

The advanced catheters from Philips that will be promoted in conjunction with HeartFlow's technology include Philips' coronary fractional flow reserve (FFR), instant wave-free ratio (iFR), and intravascular ultrasound (IVUS) solutions. Philips and HeartFlow's commercial collaboration will initially focus on the United States, with the intention to expand joint efforts globally in the near term.

The two companies are also exploring further collaborations in diagnostic imaging and advanced informatics. In addition to the commercial collaboration agreement, the two companies have entered into an exclusive agreement to co-develop an improved cath-lab X-ray image derived FFR or iFR solution, to significantly enhance workflow while improving the diagnosis and subsequent treatment of patients with CAD.

' Our commitment is to transform the patient experience and identify pathways that are personalized, high quality and at a lower price point. HeartFlow shares our mission of improving clinical outcomes and, through collaboration, we can advance our goal of helping healthcare providers decide, guide, treat and confirm the right therapy at the point of care.'

Christopher Barys

Business Leader,

Philips Image Guided Therapy Devices

10 Diagnostic Imaging Trends for 2018



Digital version